Weekly PSP Briefing — Keytruda

Week ending 19 Aug 2026 | Baseline week

1. Self-management questions this week

This is a baseline week with 10 distinct questions and 60 AI responses. Most activity was outside the PSP self-management scope, focusing on treatment choice, substitution, labeling, eligibility, and interactions.

Relevant support-journey themes:

• Administration technique/logistics: 1 question, 6 responses. The question asked: “How is Keytruda administered—IV infusion time, required dilution/infusion rate guidance, and any premedication or flush instructions?” Responses consistently described IV infusion rather than injection, including language such as “not an IV push” and “infuse over 30 minutes.”
• Dosing schedule: 1 question, 6 responses. Patients asked about the labeled adjuvant regimen for resected melanoma: “200 mg IV every 3 weeks” for “up to 1 year,” with some responses also mentioning a 400 mg every-six-week schedule.
• Missed doses, injection technique, storage/handling, titration, and day-to-day side-effect self-management: 0 direct questions identified.

The AST/ALT question concerns clinical dose management rather than patient self-management and should remain primarily with Medical Information/clinical teams, with a separate PV note only if the inconsistency is considered severe.

2. Where guidance is inconsistent or thin

Three inconsistency flags were reported, but they reflect whether certain categories were mentioned, not conflicting practical instructions:

• Administration responses varied in whether they included “do not use”/contraindication language.
• Warfarin responses varied similarly.
• Eligibility responses differed on whether infection risk was mentioned.

No disagreement was identified on a missed-dose window, injection step, storage condition, or other immediate patient action. However, the high hedging/disclaimer tally (50) suggests frequent qualification. For example, administration answers repeatedly defer to “the most current local prescribing information and your infusion center protocol.” This is appropriate for clinical precision but does not give patients a clear PSP contact or next step.

3. Support-pathway visibility

The sampled answers generally direct patients toward a local protocol, pharmacist, prescriber, or infusion center, but none visibly point to a nurse line or patient support program. This leaves a structural opportunity: patients may receive technically detailed answers without knowing who to contact for practical preparation, scheduling, or questions between visits.

4. Trend across weeks

There is no prior-week comparison. This should be treated as a baseline, not as evidence of increasing or decreasing self-management demand. The single available trend point records three inconsistency flags.

5. Recommended actions

1. Add a clear support-pathway prompt to onboarding and infusion materials. Include when to contact the nurse educator/support coordinator versus the infusion center or prescriber; this addresses the absence of PSP routing in the sampled answers.
2. Reinforce administration logistics in patient-facing materials. Clarify that Keytruda is administered by IV infusion, not self-injected, and that timing and preparation follow the treating center’s protocol.
3. Coordinate with Medical Information to verify dosing language before including the “200 mg every 3 weeks/up to 1 year” and alternative schedule wording in PSP materials.
4. Monitor next weeks for missed-dose, storage, side-effect, or injection-training questions. No proactive outreach is indicated from this baseline alone.